EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis

Kaspar Itin, Rebecca Lapides iD, Soumya Paria, Babak Saravi, Alina M Torrez, Lara Valeska Maul, Michael Wang-Evers iD, Alexander A Navarini, Dieter Manstein, Beata Kun, Leticia Szadai, Judit Olàh und 7 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.10.2026. Verfasst von Kaspar Itin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Melanoma, Neoplasm Recurrence, Local, Skin Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation SNCF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients undergoing treatment for cutaneous melanoma are generally considered cured after a period of 5 years, since most recurrences manifest within three to 5 years. However, some patients can present with a delayed recurrence of melanoma beyond a 10‐year timeframe.

Objective

To identify clinicopathologic factors associated with survival in patients with cutaneous melanoma who developed metastatic recurrence at least 5 years after primary diagnosis.

Methods

We conducted a retrospective single‐center cohort study of 30 patients with cutaneous melanoma developing metastatic recurrence at least 5 years post‐diagnosis. The cohort contained 18 women and 12 men (mean age 50.2; range 25–76). Variables included age, sex, BRAF status, site, melanoma subtype, Breslow thickness, ulceration, Clark level, regression, and recurrence localization. Overall survival (OS), progression‐free survival (PFS), and post‐recurrence survival (PRS) were evaluated via Cox proportional hazards models.

Results

Mean OS, PFS, and PRS were 168.7, 130.4, and 43.7 months, respectively. Eight patients (27%) died. Tumors averaged 2.61 mm Breslow thickness; 50.0% were BRAF‐mutant, 53.3% ulcerated, and 50.0% truncal. Recurrences were locoregional (cutaneous, subcutaneous, in‐transit, nodal) in eight (26.7%) and distant in 21 (70.0%); one lacked data. Female sex predicted better univariate OS (HR 0.055, 95% CI 0.01–0.47; p = 0.008) and multivariate PFS (HR 0.364, 95% CI 0.14–0.93; p = 0.035). Increasing age predicted shorter multivariate PFS (HR 1.072, 95% CI 1.03–1.12; p = 0.001). Histologic regression (HR 3.557, 95% CI 1.04–12.17; p = 0.043) and BRAF status (HR 0.413, 95% CI 0.18–0.94; p = 0.034) independently impacted PFS. Kaplan–Meier showed longer OS and PFS in women, and longer PFS in patients younger than 50 years.

Conclusions

Delayed recurrence can manifest over a decade post‐diagnosis. Female sex and younger age correlate with favorable survival. These findings underscore the necessity of continued clinical vigilance and patient counseling beyond 10 years, although larger cohorts are needed to validate late‐recurrence risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasm Recurrence, LocalSkin NeoplasmsHumansMaleFemaleAgedMiddle AgedRisk FactorsAdultRetrospective StudiesProto-Oncogene Proteins B-rafTime Factors

Stichwörter der Autor:innen

BRAFlate recurrencemelanomapatient managementrisk factors

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital of Basel, Basel, Switzerland.
  • Robert Larner, M.D. College of Medicine at the University of Vermont, Burlington, Vermont, USA.
  • Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.
  • Faculty of Science, Technology, Engineering & Mathematics, The Open University, Milton Keynes, UK.
  • Department of Orthopedics and Trauma Surgery, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Rebecca Lapides, Michael Wang-Evers, Eszter Baltas, Grzegorz Sarek

Förderung

  • Fondation SNCF

Zitieren

APA

Itin, K., Lapides, R., Paria, S., Saravi, B., Torrez, A. M., Maul, L. V., Wang-Evers, M., Navarini, A. A., Manstein, D., Kun, B., Szadai, L., Olàh, J., Baltas, E., Gyulai, R., Hollo, P., Sarek, G., Németh, I. B., Adhikari, K., & Roider, E. (2026). Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72389

Vancouver

Itin K, Lapides R, Paria S, Saravi B, Torrez AM, Maul LV, et al. Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72389

BibTeX
@article{Itin2026,
  author = {Itin, Kaspar and Lapides, Rebecca and Paria, Soumya and Saravi, Babak and Torrez, Alina M and Maul, Lara Valeska and Wang-Evers, Michael and Navarini, Alexander A and Manstein, Dieter and Kun, Beata and Szadai, Leticia and Olàh, Judit and Baltas, Eszter and Gyulai, Rolland and Hollo, Peter and Sarek, Grzegorz and Németh, Istvan B and Adhikari, Kaustubh and Roider, Elisabeth},
  title = {Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72389}
}
Kostenlos starten →